New appointment at NormOxys
This article was originally published in Scrip
NormOxys, a US biotechnology company developing a class of small-molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, has appointed Dr Martin Tolar president and chief executive officer. Dr Tolar was most recently chief scientific officer and later executive vice-president and chief business officer at CoMentis. NormOxys has also leased a 3,500ft2 space in Wellesley, Massachusetts, to serve as its new corporate headquarters.